in Xenopus and chick embryos using the powerful and general TGFb inhibitor, Smad7, which inhibits both Smad1-(BMP) and Smad2-(Nodal/Activin) mediated pathways. We confirm that Smad7 efficiently inhibits phosphorylation of Smad1 and Smad2. Surprisingly, however, over-expression of Smad7 in Xenopus ventral epidermis induces expression of the dorsal mesodermal markers Chordin and Brachyury. Neural markers are induced, but in a noncell-autonomous manner and only when Chordin and Brachyury are also induced. Simultaneous inhibition of Smad1 and Smad2 by different approaches does not account for all Smad7 effects, indicating that Smad7 has activities other than inhibition of the TGFb pathway. We provide evidence that these effects are independent of Wnt, FGF, Hedgehog and retinoid signalling. We also show that these effects are due to elements outside of the MH2 domain of Smad7. Together, these results indicate that BMP inhibition is not sufficient for neural induction even when Nodal/Activin is also blocked, and that Smad7 activity is considerably more complex than had previously been assumed. We suggest that experiments relying on Smad7 as an inhibitor of TGFb-pathways should be interpreted with considerable caution.
Introduction
BMPs are members of the transforming growth factor b (TGFb) family of secreted proteins. The main mechanism of signal transduction for these proteins involves two serine/ threonine kinase receptors: type-I and type-II. Upon ligand binding the receptor complex phosphorylates particular members of the Smad family of proteins, the receptor regulated Smads (R-Smads) (Hill, 2001; Massague et al., 2005; Park, 2005; Shi and Massague, 2003; ten Dijke and Hill, 2004;  0925-4773/$ -see front matter Ó 2008 Elsevier Ireland Ltd. All rights reserved. doi:10.1016/j.mod.2008.02.002
von Bubnoff and Cho, 2001) . Phosphorylated R-Smads are released from the receptor complex and bind to Smad4, allowing the translocation of this complex to the nucleus, where it regulates transcription of target genes (von Bubnoff and Cho, 2001) . Other than the R-Smads and Smad4, inhibitory Smads (I-Smads) have been shown to be important regulators of this pathway. Two major I-Smads have been characterized: Smad-6, which preferentially inhibits the BMP pathway and Smad-7, which blocks all TGFb signalling. I-Smads bind to the intracellular domain of receptor type-I, recruit Smurf ubiquitin ligases and induce degradation of the receptor (Hill, 2001 ; ten Dijke and Hill, 2004) . In addition, Smad6 inhibits BMP signalling by competing with Smad4 for binding to phosphorylated Smad1, yielding inactive Smad1-Smad6 complexes (Hata et al., 1998) . Through these mechanisms ISmads inhibit the TGFb pathway in a cell-autonomous way.
BMP signalling plays numerous roles in development. One of the best studied processes involving regulation of BMP signalling is neural induction -an early embryonic event first demonstrated clearly almost a century ago when it was shown that signals emanating from the organizer (the dorsal lip of the blastopore in amphibians) can instruct ectoderm to acquire a neural fate (Spemann and Mangold, 1924) . The first molecular explanation for this process (the ''default model'') is that BMPs, which are broadly expressed in the early embryo, act as epidermal inducers and need to be inhibited in the prospective neural plate for this structure to form (Harland, 2000; Hemmati-Brivanlou and Melton, 1997a; Hemmati-Brivanlou and Melton, 1997b; Muñ oz-Sanjuá n and Brivanlou, 2002) . Although there is some controversy concerning whether or not the default model provides a sufficient explanation for this process (see for example Bachiller et al., 2000; Belo et al., 2000; Bertrand et al., 2003; Delaune et al., 2005; Linker and Stern, 2004; McMahon et al., 1998; Mukhopadhyay et al., 2001; Stern, 2004; Streit et al., 2000 Streit et al., , 1998 Streit and Stern, 1999a) it is clear that inhibition of BMP signalling is part of the neural induction process in vertebrates.
One of the ways in which the involvement of BMPs as epidermal inducers and neural inhibitors has been tested in Xenopus is by misexpression of the powerful inhibitory Smad, Smad7, a double-inhibitor of both the and 2-,3-dependent (Nodal/Activin) TGFb-pathways (Casellas and Brivanlou, 1998; Chang and Harland, 2007; Nakao et al., 1997; Nakayama et al., 2001) . Here, we use this reagent to re-examine the role of BMP signalling in neural induction in Xenopus and chick. We confirm that Smad7 efficiently inhibits the phosphorylation of both Smad1 and Smad2. Over-expression of Smad7 does not induce neural markers in chick competent ectoderm. Surprisingly, in Xenopus, over-expression of Smad7 in ventral epidermis induces Chordin and Brachyury, markers of dorsal mesoderm, and as a secondary effect, neural markers are induced in a non-cell-autonomous manner. These effects cannot be explained entirely by inhibition of all (Nodal/Activin and BMP-related) TGFb signalling, because inhibition of Nodal/Activin-related signalling by co-injection of either Cerberus-Short (CerS) or a truncated form of a type I receptor (tAlk4), together with inhibition of BMP-related signals by either Smad6 or a truncated version of Smad7 (lacking the MH1 domain) does not produce the same effects. These results suggest that Smad7 has activities other than inhibition of TGFb-pathways and that these activities are due to functional elements outside of the MH2 domain. We also provide evidence that the effects of Smad7 unrelated to TGFb signalling are independent of Wnt, FGF, hedgehog and retinoid signalling. Although these activities of Smad7 remain only partially understood, this study suggests that great caution should be exercised in interpreting the results of experiments using Smad7 as a BMP/TGFb antagonist.
Results

Smad7 does not induce neural markers in the chick
Previous work has shown that BMP inhibition, through over-expression of soluble or cell-autonomous antagonists, does not induce neural markers in chick epiblast (Linker Stern, 2004; Streit et al., 1998) . It is possible that the absence of neural induction in these assays is due to an incomplete inhibition of the BMP pathway. Since it has been reported that Smad7 is one of the most effective BMP inhibitors (Casellas and Brivanlou, 1998; Ishisaki et al., 1999; Nakao et al., 1997; Nakayama et al., 2001) , we used this to test whether Smad7 can induce neural markers in chick. When Smad7 was electroporated into the area opaca of stage 3+ embryos, either alone or in combination with other BMP inhibitors, no expression of mesodermal (brachyury, chordin) or neural (Sox2) markers was observed after 18-20 h incubation (Smad7, 0/12; other BMP inhibitors 0/9; Fig. 1 and Supplementary Fig. 1) . Thus, consistent with previous observations (Linker and Stern, 2004) , inhibition of BMP is not sufficient to induce Sox2 in competent chick epiblast.
2.2.
Neural induction by Smad7 in Xenopus is a secondary effect of dorsal mesoderm induction Some studies have reported that in Xenopus ventral epidermis, as in the chick, inhibition of BMP is not sufficient to induce neural markers (Chang and Harland, 2007; Delaune et al., 2005; Linker and Stern, 2004) . However, the possibility remains that BMP signalling was not completely inhibited in these studies. We therefore tested the activity of Smad7 in Xenopus embryos (Fig. 2) . When injected into the ventral marginal zone of 4-8 cell stage embryos (where it should block mainly BMP signals), Smad7 (2 ng) induces dorsal tissues and an ectopic axis (42/50; not shown), confirming that Smad7 does act as previously described (Casellas and Brivanlou, 1998) . To test the efficiency of Smad7, we analysed the levels of phosphorylation of Smad1 and Smad2 in Smad7-injected animal caps. Both are greatly reduced ( Fig. 3A and B) , confirming the potent inhibitory effect of Smad7 on both Nodal/Activin (Smad2-dependent) and BMP-related (Smad1-dependent) TGFb signalling (Casellas and Brivanlou, 1998) .
Next, we analysed whether Smad7 can induce neural markers in ventral ectoderm. 32-cell-stage embryos were injected into the A4 blastomere and cultured to stage 18. In these experiments both Sox3 (66/72) and Sox2 (47/58) are induced in ventral epidermis ( Fig. 2A-E ). To test whether this induction is direct, we analysed the expression of mesodermal markers. We were surprised to find that Smad7 strongly induces the organizer/notochord markers chordin (52/52; In normal embryos, chordin is expressed at low levels in the anterior neural plate (in addition to stronger expression in the notochord). To test the possibility that the Smad7-induced chordin expression represents anterior neural plate rather than dorsal mesoderm, we analysed the expression of Six3, a specific marker for anterior neural tissue. Six3 was never expressed in Smad7-injected Chordin induction after injection into the A4 blastomere. 2 ng: Sox3 92%, Sox2 81%, Chordin 100%; 1-0.5 ng: Sox3 89%, Sox2 80%, Chordin 100%; 100 pg: Sox3 66%, Sox2 36%, Chordin 91%; 50 pg: Sox3 33%, Sox2 14%, Chordin 88%; 10 pg: Sox3 0%, Sox2 0%, Chordin 72%. (D) The induction of Sox3 is not cell-autonomous to the progeny of the Smad7-injected A4 blastomere. Embryos were injected with either Rldx or Smad7+Fldx in the A4 blastomere at the 32-cell stage, and isotopic transplants performed at stage 8, replacing Rldx-labelled cells with the progeny of Smad7(2 ng)+Fldx-injected cells. Embryos were grown to stage 18 and stained for One concern raised by this experiment is the possibility of non-specific effects due to the high dose of Smad7 used (2 ng mRNA). We therefore analysed the response of neural and mesodermal markers to different doses of Smad7. As the concentration decreases, neural markers are lost first, until at 10 pg only dorsal mesodermal markers are induced (Fig. 3C) . These results strongly suggest that the induction of neural markers in ventral epidermis by Smad7 is indirect, a secondary consequence of mesoderm induction. Consistent with this, histological sections reveal Chordin expression in LacZpositive cells (derived from the injected blastomere; Fig. 2J ), while Sox3 expression is observed in both LacZ-positive and -negative cells, some of which are located more than 7 celldiameters away from the nearest descendants of the injected cell (Fig. 2C ). This suggests that the induction of neural markers is not cell-autonomous to the Smad7-injected cells. To confirm this, we used transplantation to test whether Smad7-injected cells are able to induce neural markers in neighbouring cells. Smad7-injected cells were grafted isotopically into control host embryos (Fig. 3D) . Sections reveal Sox3 expression in host cells (Fig. 3E) , confirming that the neural inducing effect of Smad7 is not cell-autonomous. In conclusion, Smad7 induces neural markers in a non-cell-autonomous manner, through a prior induction of dorsal mesendoderm.
Smad7 has activities distinct from inhibition of TGFb signalling
The unexpected induction of dorsal mesoderm by Smad7 described above could indicate that a different signalling pathway is involved in its ability to induce neural and/or mesodermal markers. Since Smad7 antagonises both BMP and Nodal signalling we tested whether this effect could be mimicked by separate inhibition of both pathways using other antagonists. We injected a combination of the BMP inhibitor Smad6 (1-4 ng) together with either the secreted Nodal inhibitor Cerberus-Short (CerS, 1.5-2 ng; Piccolo et al., 1999) or with the Activin inhibitor, truncated TGFb receptor type I (tAlk4, which acts cell-autonomously; Chang et al., 1997) . These combinations only partially mimic the effects of Smad7. Chordin is induced in both cases (Smad6+ CerS:110/112, Fig It is possible that these results are due to differences in the level of Smad1 and/or Smad2 inhibition resulting from each combination of factors. However, the levels of phosphorylated Smad1 and Smad2 are similar in all three combinations (Fig. 3A-B) , indicating that inhibition of the Smad1 and Smad2 pathways alone cannot account for all of the effects of Smad7 injection.
The C-terminal (MH2) domain of Smad7 is responsible for the BMP inhibitory functions of the protein (Nakayama et al., 2001) . We tested whether expression of this domain together with inhibition of the Nodal/Activin signalling by CerS could recapitulate the effects of Smad7. An inducible form of the MH2 domain (Wawersik et al., 2005 ) (DSmad7 10pg; Supplementary Fig. 2 ) was injected together CerS (1 ng) into the A4 blastomere. This combination (similar to Smad6+CerS or Smad6+Alk4, see above) only partially mimicked the effect of Smad7 injections. Chordin is induced ( Fig. 5K-L ; 36/39), but neural markers are not ( Fig. 5G-J ; Sox2: 0/42, Sox3: 1/28). This experiment confirms that simultaneous inhibition of BMP-and Nodal/Activin-pathways does not recapitulate all of the activities of Smad7. It also shows that the additional activities reside outside of the MH2 domain.
The loss of neural marker induction in these experiments raises the possibility that a Nodal activity, emitted by Smad7-injected cells, is responsible for the non-cell-autonomous induction of neural markers in adjacent cells ( Fig. 2A-C,  Fig. 3D-E) . To test this directly, we co-injected the secreted 
2.4.
Smad7 activities are independent of FGF, Wnt, retinoid and hedgehog signalling Together with Nodal, FGF and Wnt/b-catenin signalling are the major pathways implicated in mesoderm induction (Kimelman and Bjornson, 2004; Kimelman et al., 1992; Kimelman and Kirschner, 1987) , raising the possibility that the induction of dorsal mesoderm by Smad7 might be due to activation of one of these pathways. Furthermore, the induction of neural markers (Sox2 and Sox3) by misexpression of Smad7 in A4 was shown to be non-cell-autonomous, suggesting that a factor secreted by the induced dorsal mesoderm is responsible for the neural induction. To examine which factors might underlie both of these activities, we inhibited Wnt/b-catenin or FGF signalling in Smad7-injected embryos. GSK3 is an intracellular inhibitor of Wnt/b-catenin signalling. Overexpression of GSK3 (2 ng) in one half of the embryo efficiently inhibits Slug expression (31/54, not shown; Bastidas et al., 2004) Fig. 6E-F ). We then tested the possible involvement of FGF signalling in the effects of Smad7, using the FGF-receptor inhibitor SU5402 (Mohammadi et al., 1997) . Embryos cultured in SU5402 (120 lM; Delaune et al., 2005) from the 32-cell-stage fail to gastrulate and do not produce neural or mesodermal tissue (Fig. 6G-I) , confirming that the inhibitor is effective. Nevertheless, injection of Smad7 into A4 still induces Sox3 (30/30, Fig. 6G ), Sox2 (27/29, Fig. 6H ) and Chordin (26/27, Fig. 6I ) when these embryos are grown in SU5402, while the normal expression of these genes in the same embryos is abolished.
Another barely studied pathway that has been implicated in neural induction involves retinoids Sharpe, 1991; Sharpe and Gurdon, 1990) . To test whether these may underlie the non-cell-autonomous effects of Smad7 we incubated Smad7-injected embryos in the retinoid antagonist citral (Schuh et al., 1993) . At a concentration sufficient to affect axial patterning (at 60-90 lM 21/21 embryos displayed defects in hindbrain patterning; not shown), incubation in citral did not inhibit the induction of Sox3 (18/19), Sox2 (14/15) or Chordin (4/6) in Smad7-injected embryos (not shown). Finally, since Sonic Hedgehog is expressed in the late organizer and in its midline derivatives (Charrier et al., 2002 (Charrier et al., ,1999 Krauss et al., 1993; Roelink et al., 1994) , we used cyclopamine to test whether Hedgehog signalling might be responsible for the non-cell-autonomous effects. At concentrations sufficient to cause holoprosencephaly (100 lM, 32/32 with defects; not shown) (Dunn et al., 1995; Martin et al., 2007; Perron et al., 2003) , cyclopamine did not inhibit the induction of Sox3 (7/7) or Sox2 (8/8) in Smad7-injected embryos (not shown). Taken together, these results suggest that the unexplained effects of Smad7 are mediated by a pathway other than Wnt/b-catenin, FGF, retinoids or Hedgehog.
Discussion
Smad7 induces neural tissue only indirectly
Previous studies showed that inhibition of BMP is not sufficient to trigger neural induction either in Xenopus or in chick (Delaune et al., 2005; Launay et al., 1996; Linker and Stern, 2004; Sasai et al., 1996 Sasai et al., , 1998 . To confirm this conclusion we used the more potent TGFb inhibitor Smad7. We find that neither in chick nor in Xenopus is Smad7 able to induce neural tissue directly. While in chick the expression of Smad7 in competent epiblast does not induce any of the markers tested, dorsal mesodermal markers are induced in Xenopus along with neural markers. This indicates that the neural induction by Smad7 in Xenopus is indirect, a secondary consequence of dorsal mesoderm induction. In agreement with this conclusion, as the concentrations of Smad7 are reduced, neural markers disappear first until, at 10pg, only dorsal mesodermal markers are induced. Moreover, grafting experiments show that induction of mesodermal markers is cell-autonomous, whereas induction of neural markers is not. These results strongly argue that the ''neural inducing'' activity of Smad7 is indirect and cannot be explained solely by its inhibition of the BMP pathway in the injected cells.
It is possible that Smad7 acts by dorsalising some prospective ventral mesoderm descendants of the injected cell. We used two lineage markers: fluorescein and LacZ. The former allowed us to see cells entering the blastopore at gastrula stage in a few embryos (where the wrong cell may have been targeted), and these were discarded. The latter was used at the end of the experiment, and again, embryos with labelled cells in regions outside the ventral epidermis were discarded. In all control embryos, labelled cells end up exclusively in ventral epidermis, consistent with the fate maps of Dale and Slack (1987) . This makes it unlikely that the primary effect of Smad7 is dorsalisation of mesoderm in this assayneural marker expression is only seen when Chordin/Brachyury are also expressed, again strongly suggesting that this neural induction is indirect. These results conflict directly with a recent report (Chang and Harland, 2007) claiming that simultaneous inhibition of Smad1-mediated BMP signals and of Smad2-mediated Nodal/Activin signalling is sufficient for neural induction. However, the figures in their study (Fig. 2, 3 and 5 of Chang and Harland, 2007) reveal clearly that this induction is also noncell-autonomous to the injected cells, similar to what we have found here. Therefore both studies support the notion that inhibition of TGFb-related pathways is not sufficient for neural induction.
Unexpected effects of Smad7
It is particularly surprising that Smad7, which inhibits both the Smad1/5/8-mediated pathway (used by BMPs) and the Smad2/3-pathway (used by Nodal/Activin), paradoxically induces dorsal mesoderm, especially since it is well established that mesoderm induction is mediated by Nodal/Activin (Kessler, 2004; Kimelman and Bjornson, 2004; Schier, 2004) . We had expected no mesoderm to be induced by Smad7 since the Smad2-dependent signalling pathway downstream of Nodal/ Activin is blocked. Several recent reports suggest that Smad7 may have other functions in addition to being an inhibitory Smad. One study (Liu et al., 2006) reported a direct association between Smad7, Arkadia (a Nodal effector) and the Wnt effector Axin as part of a larger complex, opening the possibility that this complex somehow provides a link between the Nodal and Wnt pathways. Another possible mechanism arises from the discovery (Edlund et al., 2005; Han et al., 2006) of connections that include induction of b-catenin by Smad7 as well as a direct physical association between these two proteins and with Lef1. In mouse skin, Smad7 promotes the degradation of b-catenin, perhaps via its association with the ubiquitin ligase Smurf1 . These findings prompted us to test whether canonical Wnt signalling might be implicated in the effects of Smad7. Inhibition of the Wnt/b-catenin pathway by GSK3 does not alter the mesodermal inducing activity of Smad7, indicating that this effect is not due to activation of the Wnt pathway. In addition, it has been reported that Smurf1 can inhibit the JNK MAPK cascade (involved in FGF signalling) by targeting MEKK2 for degradation (Yamashita et al., 2005) , raising the possibility that the FGF pathway could be affected by misexpression of Smad7 in our experiments. However, we find that the mesodermal inducing activity of Smad7 is unaffected by the FGF-receptor inhibitor, SU5402. Although the possibility remains open that the effects of Smad7 on FGF signalling may occur downstream of this receptor, our results suggest that the mesoderm inducing activity of Smad7 is independent of the activation of the Wnt/bcatenin or FGF signals, and that the non-cell-autonomous effects of Smad7 on induction of neural markers is also unlikely to involve either of these pathways. Likewise, we show that neither retinoid nor hedgehog signalling accounts for the non-cellautonomous neural inducing effects of Smad7 injection.
It remains possible that, rather than affecting a different pathway, Smad7 alters the balance between levels of activation of the Smad1/5/8 and Smad2/3 pathways, and it is this balance rather than the absolute levels of any one phosphorylated Smad, that determines whether ventralization (BMPdependent) or mesoderm induction and dorsalization (Nodal/Activin-dependent) occurs. However, our experiments confirm the finding that Smad7 inhibits both Smad1 and Smad2 phosphorylation (Casellas and Brivanlou, 1998) , therefore this still does not provide a satisfactory explanation for the results obtained. Moreover, inhibition of the Smad1 and the Smad2 pathways by co-injection of Smad6 (or truncated Smad7) and CerS (or Alk4) does not completely mimic the effects of Smad7, which further supports the idea that the mesoderm inducing activity of Smad7 cannot be explained solely by an inhibition of Smad-dependent pathways.
For the moment therefore we can only conclude that there is considerably more complexity to the activity of Smad7 than has hitherto been assumed. We suggest that experiments relying on Smad7 as an inhibitor of Smad pathways should be interpreted with considerable caution.
Experimental procedures
Xenopus
Xenopus oocytes were fertilised in vitro and embryos staged according to Nieuwkoop and Faber (1967) . Injections were performed as described (Marchant et al., 1998) into the A4 blastomere at the 32-cell-stage or into one of its descendants at the 64 cell stage. Capped mRNAs were made with mMessage mMachine (Ambion) as described (Linker and Stern, 2004) . mRNA was transcribed from Smad7-pBSK (kind gift of Ali H. Brivanlou (Casellas and Brivanlou, 1998) , DSmad7-pCS2+, TEV2GR-pCS2+ (kind gifts of M. Whitman; Wawersik et al., 2005) , Smad6-pCS2+ (Linker and Stern, 2004; Yamada et al., 1999) , CerberusShort-pCS2+ (kind gift of E M de Robertis; Piccolo et al., 1999) , and GSK3-pCS2 (kind gift of S. Wilson; Shimizu et al., 2000) , tAlk4 (kind gift of C. Chang et al., 1997) , the mRNA was injected together with 200-600 pg of nuclear LacZ mRNA (kind gift of Ali H. Brivanlou) as a lineage tracer. The accuracy of injection was assessed by the fate of the progeny of the injected cell: embryos with labelled cells in regions other than the ventral epidermis were discarded.
To investigate the cell autonomy of Smad7 effects, a host embryo was injected with rhodamine lysine dextran (Rdlx) in A4 and a donor with fluorescein lysine dextran (Fdlx) together with Smad7 in the same blastomere. After culture at 14°C for 3-3.5 h to early stage 8, isotopic grafts were performed to replace RDX cells with Smad7/FDX cells. Embryos were allowed to heal in NAM for 1 h and grown overnight (to stage 17) in 1/10 NAM at 14°C. Paraffin sections were performed as described (Linker and Stern, 2004) .
The FGF-receptor inhibitor SU5402 (Calbiochem) was dissolved in DMSO at 30 mM and was used at 160 lM (Delaune et al., 2005; Mohammadi et al., 1997) . The retinoid inhibitor citral (Sigma) was made up as a 60 mM stock in ethanol and was used at 60-90 lM (Schuh et al., 1993) . The hedgehog antagonist cyclopamine (Sigma) was made up as a 10 mM stock in ethanol and was used at 100 lM (Dunn et al., 1995; Martin et al., 2007; Perron et al., 2003) .
Whole cell extracts from Xenopus animal caps explants and Western blotting procedures were performed as described (Dorey and Hill, 2006) . The following commercial antibodies were used: anti-phosphorylated Smad2 (465/467, Cell Signalling Technology), anti-phosphorylated Smad1 (463/465, Cell Signalling Technology), anti-Smad2/3 (BD Biosciences Pharmingen), anti-Smad1 (Upstate) and anti-tubulin (YL1/2, AbCam).
Chick experiments
Fertilised hens' eggs (Brown Bovan Gold; Henry Stewart) were incubated at 38°C and staged according to Hamburger and Hamilton (1951) . Factors were delivered to the inner third of the lateral/anterior area opaca at stage 3 + /4 by electroporation or by grafting transfected COS cells. Electroporation was performed as previously described (Sheng et al., 2003) using the following cloned into pCAb: xSmad7 (Casellas and Brivanlou, 1998) , cSmad6 (Linker and Stern, 2004; Yamada et al., 1999) , cChordin (Streit et al., 1998) , Xenopus truncated BMP receptor (tBR; Linker and Stern, 2004; Suzuki et al., 1994) and cCerberus (Bertocchini et al., 2004; Zhu et al., 1999 ). An expression plasmid (pCDNAII) encoding Noggin (Streit and Stern, 1999b) , was used to transfect COS cells as previously described (Streit et al., 1998) .
In situ hybridisation and whole mount immunocytochemistry were performed as previously described (Stern, 1998) . In situ hybridisation with Sox2 always produces background staining in grafted cell pellets; expression of the markers in the host was therefore assessed in histological sections.
